Compound ID | 187

Update compound information

Lefamulin (BC-3781)

Class: Pleuromutilin

Spectrum of activity: Gram-positive  &  Gram-negative
Details of activity: Acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia
Institute where first reported: Nabriva Therapeutics, Austria
Year first mentioned: 2011
Highest developmental phase: Approved by FDA in 2019
Development status: Approved
External links:
Guide to Pharmacology: lefamulin
Main Source: http://www.nabriva.com/programs/pipeline/
Citations:
  • http://aac.asm.org/content/57/5/2087.full
  • http://aac.asm.org/content/59/1/282.full
  • https://www.escmid.org/escmid_publications/escmid_elibrary/?q=lefamulin&id=2173&L=0&x=0&y=0

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us.

    Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.